- Home
- VSCO vs NAMS Comparison
VSCO vs NAMS Comparison
Compare VSCO & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VSCO | NAMS |
|---|---|---|
| Founded | 1977 | 2019 |
| Country | United States | Netherlands |
| Employees | N/A | 100 |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.5B |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | VSCO | NAMS |
|---|---|---|
| Price | $52.23 | $35.15 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 8 |
| Target Price | ★ $54.55 | $46.75 |
| AVG Volume (30 Days) | ★ 2.3M | 794.4K |
| Earning Date | 03-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.93 | N/A |
| Revenue | ★ $6,553,000,000.00 | N/A |
| Revenue This Year | $8.77 | $17.96 |
| Revenue Next Year | $3.68 | $540.65 |
| P/E Ratio | $26.70 | ★ N/A |
| Revenue Growth | ★ 5.18 | N/A |
| 52 Week Low | $15.34 | $14.92 |
| 52 Week High | $66.89 | $42.00 |
Technical Indicators
Market Signals| Indicator | VSCO | NAMS |
|---|---|---|
| Relative Strength Index (RSI) | 57.36 | 63.58 |
| Support Level | $43.05 | $34.05 |
| Resistance Level | $66.23 | $37.43 |
| Average True Range (ATR) | 2.45 | 1.80 |
| MACD | 1.29 | 0.63 |
| Stochastic Oscillator | 90.97 | 99.46 |
Price Performance
Historical ComparisonAbout VSCO Victorias Secret & Co.
Victoria's Secret & Co is a retailer of women's intimate and other apparel and beauty products marketed under the Victoria's Secret, PINK, and Adore Me brand names. It also includes the merchandise sourcing and production function serving the Company and its international partners. The Company operates as a single segment designed to serve customers seamlessly through stores and online channels. The Company also includes the merchandise sourcing and production function serving the Company and its international partners.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.